Research & Development

 Carefully controlled research and development is the essential process for safe, more effective, less toxic treatments to be made available for the people who need them. Pretrial development is actively underway for several such agents and combination therapies. 

First, Precision Immunotherapeutics has acquired the development rights for U.S. patent 9,034,310 which describes a novel combination immunotherapy, particularly for patients with cancers resistant to existing standard of care therapies. This is actively under development along with advantageous and potentially superior delivery mechanisms for some of the agents involved. 

We are also developing partnerships for additional innovative agents which show promise for yielding more effective, less toxic, and ultimately less expensive treatments for a number of diseases in our target areas of cancer, infectious disease, and autoimmune disease.

While we continue the exacting process towards eventual submission for FDA consideration, some of these therapies are available now for ethically selected patients in the form of off label usage of existing medicines. This may occur either by itself or in conjunction with standard of care therapies especially in cancer treatment. For more information please see NeoPlas Innovation.